Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves.

27 Feb 2016

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).

26 Feb 2016

Amgen announces availability of Kyprolis (carfilzomib) in the UK for treatment of relapsed multiple myeloma

Amgen today announced that Kyprolis in combination with lenalidomide and dexamethasone is now available in the UK for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

16 Feb 2016

NCCN publishes new guidelines with NCCN Evidence Blocks for Breast, Colon, Kidney, and Rectal Cancers

The National Comprehensive Cancer Network has published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks™ for Breast, Colon, Kidney, and Rectal Cancers.

15 Feb 2016

Yale Cancer Center researchers identify cause of myeloma

Yale Cancer Center researchers have identified what causes a third of all myelomas, a type of cancer affecting plasma cells. The findings, published in the Feb. 11 issue of the New England Journal of Medicine, could fundamentally change the way this cancer and others are treated.

11 Feb 2016

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

International biopharmaceutical company Specialised Therapeutics Asia will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar.

3 Feb 2016

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.

30 Jan 2016

$SIRIUS supports single-agent daratumumab in refractory multiple myeloma$

SIRIUS supports single-agent daratumumab in refractory multiple myeloma

Phase II trial results show that daratumumab monotherapy elicits responses and has a favourable adverse event profile in heavily-pretreated, refractory multiple myeloma patients.

19 Jan 2016

IQWiG finds no added benefit for pomalidomide drug in multiple myeloma

Pomalidomide (trade name: Imnovid) has been approved since 2013 for the treatment of multiple myeloma that has returned and is difficult to treat. The drug is an option for adults who have received two or more prior treatment regimens, including treatment with the drugs lenalidomide and bortezomib, and in whom the last treatment had no sufficient effect.

13 Jan 2016

People with low sunlight exposure and vitamin D deficiency at greater risk of developing leukemia

Epidemiologists at University of California, San Diego School of Medicine report that persons residing at higher latitudes, with lower sunlight/ultraviolet B (UVB) exposure and greater prevalence of vitamin D deficiency, are at least two times at greater risk of developing leukemia than equatorial populations.

7 Jan 2016

HealthWell Foundation opens new fund to provide financial assistance to Medicare patients suffering from RCC

The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, today announced it has opened a new fund to provide financial assistance to Medicare patients suffering from renal cell carcinoma (RCC).

31 Dec 2015

Drug that boosts activity in the brain's 'garbage disposal' system may slow Alzheimer's disease

A drug that boosts activity in the brain's "garbage disposal" system can decrease levels of toxic proteins associated with Alzheimer's disease and other neurodegenerative disorders and improve cognition in mice, a new study by neuroscientists at Columbia University Medical Center has found.

22 Dec 2015

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

Bio Light Israeli Life Sciences Investments Ltd., an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that its IOPtiMate system for the treatment of glaucoma has been approved by the Canadian Medical Devices Bureau, allowing the Company to commercialize the surgical system in Canada.

21 Dec 2015

$Role for carfilzomib in relapsed, refractory multiple myeloma treatment$

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

Carfilzomib significantly improves outcomes in previously treated patients with relapsed or refractory multiple myeloma, shows a head-to-head comparison with bortezomib.

11 Dec 2015

BioLight announces first sale of IOPtiMate system in Portugal

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate system to a medical center located in Portugal.

8 Dec 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma.

8 Dec 2015

Lancet study compares prices of new cancer drugs in high-income countries

The price of new cancer drugs varies widely (from 28% to 388%) between high-income countries in Europe, Australia, and New Zealand, new research published in The Lancet Oncology has found.

8 Dec 2015

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.

8 Dec 2015

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

Yale researchers develop vaccine strategy that reduces risk of flu in cancer patients

Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.

7 Dec 2015

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

Amgen announces availability of Kyprolis (carfilzomib) in the UK for treatment of relapsed multiple myeloma

NCCN publishes new guidelines with NCCN Evidence Blocks for Breast, Colon, Kidney, and Rectal Cancers

Yale Cancer Center researchers identify cause of myeloma

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

SIRIUS supports single-agent daratumumab in refractory multiple myeloma

IQWiG finds no added benefit for pomalidomide drug in multiple myeloma

People with low sunlight exposure and vitamin D deficiency at greater risk of developing leukemia

HealthWell Foundation opens new fund to provide financial assistance to Medicare patients suffering from RCC

Drug that boosts activity in the brain's 'garbage disposal' system may slow Alzheimer's disease

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

BioLight announces first sale of IOPtiMate system in Portugal

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Lancet study compares prices of new cancer drugs in high-income countries

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

New approaches to treating leukemia, lymphoma and myeloma

Yale researchers develop vaccine strategy that reduces risk of flu in cancer patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in